Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00035100 |
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.
Condition | Intervention | Phase |
---|---|---|
Ovarian Neoplasms Peritoneal Neoplasms Fallopian Tube Neoplasms |
Drug: epothilone b |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
The following patients may be eligible for the study:
Exclusion Criteria
The following patients are not eligible for the study:
United States, California | |
California Pacific Medical Center | |
San Francisco, California, United States, 94116 | |
United States, Connecticut | |
St. Francis Hospital | |
Hartford, Connecticut, United States, 06105 | |
United States, Maryland | |
The Sidney Kimmel Comprehensive Cancer Center | |
Baltimore, Maryland, United States, 21287 | |
United States, Nevada | |
Women's Cancer Center of Nevada | |
Las Vegas, Nevada, United States, 89109 | |
United States, Rhode Island | |
Women and Infants Hospital | |
Providence, Rhode Island, United States, 02905 | |
United States, Tennessee | |
Sarah Cannon Cancer Center | |
Nashville, Tennessee, United States, 37203 | |
United States, Utah | |
Huntsman Cancer Institute, University of Utah | |
Salt Lake City, Utah, United States, 84112 |
Study Chair: | Novartis | Novartis |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CEPO906A2203 |
Study First Received: | May 2, 2002 |
Last Updated: | December 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00035100 |
Health Authority: | United States: Food and Drug Administration |
ovarian ovary peritoneal cancer fallopian cancer cancer tumor |
tumour neoplasm carcinoma intravenous epothilone |
Ovarian cancer Epothilone B Digestive System Neoplasms Ovarian Neoplasms Gonadal Disorders Epothilones Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Abdominal Neoplasms |
Fallopian Tube Neoplasms Carcinoma Fallopian Tube Diseases Genital Diseases, Female Digestive System Diseases Peritoneal Diseases Gastrointestinal Neoplasms Endocrinopathy Fallopian tube cancer Peritoneal Neoplasms Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses |
Mitosis Modulators Tubulin Modulators Antimitotic Agents Pharmacologic Actions Adnexal Diseases |